MediWound to Report Third Quarter 2024 Financial Results
MediWound's (NASDAQ:MDWD) investors will be pleased with their stellar 125% return over the last year [Yahoo! Finance]
MediWound Ltd. (NASDAQ: MDWD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit